Microneedle Array Vaccine Delivery via Biodegradable Polymer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine administration methods, such as direct injection into muscle tissue, are inefficient due to low antigen-presenting cell density and cause pain and bleeding, leading to poor patient compliance, while transcutaneous immunization methods using ordinary needles are not always effective for vaccine delivery.
Innovation Solution
A microprojection array comprising a planar base and a plurality of microprojections made of a biodegradable polymer, with a vaccine layer that can be inserted into the skin to facilitate antigen delivery to Langerhans cells, enhancing immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If vaccines are administered via direct injection into muscle tissue, then the vaccine delivery is simple and convenient, but the antigen-presenting cell density is low and pain and bleeding occur
Solution Approach 1:
The invention divides the skin into multiple layers (stratum corneum, epidermis, dermis) and targets specific layers containing antigen-presenting cells, rather than injecting into muscle tissue. This segmentation allows precise delivery to Langerhans cells in the epidermis or dermal APCs in the dermis, improving immunogenicity while avoiding muscle tissue damage.
Solution Approach 2:
The patent uses microneedles as an intermediary device to deliver vaccines through the stratum corneum barrier to target APC-rich layers. The microneedles serve as a mediator that enables transcutaneous delivery without requiring deep muscle injection, thus achieving both convenience and effectiveness.
2Reliability
If ordinary needles are used for transcutaneous immunization, then the vaccine can be delivered to the skin, but the method is not always effective for vaccine delivery
Solution Approach 1:
The invention creates localized micro-channels through the stratum corneum using microneedles, rather than creating a large wound with ordinary needles. This localized approach delivers vaccine directly to APC-rich areas while minimizing damage to blood vessels and nerves, reducing pain and bleeding.
Solution Approach 2:
The patent changes the physical parameters of needle insertion by using microneedles with diameters of 1-100 micrometers, which are significantly smaller than ordinary needles. This parameter change allows penetration of the stratum corneum without damaging deeper vascular structures, eliminating pain and bleeding while maintaining effective vaccine delivery.
3Reliability
If microneedle arrays are used for vaccine delivery, then the antigen can be concentrated at the skin surface, but the device complexity increases
Solution Approach 1:
The patent uses microneedle arrays that can be mass-produced using replication techniques such as molding or stamping. The array structure copies the same microneedle geometry across multiple elements, enabling standardized manufacturing and reducing device complexity despite the multiple-component structure.
Solution Approach 2:
The microneedle array is mounted on a flexible substrate or backing layer that allows the array to conform to the skin surface. This flexible support structure simplifies the overall device design by providing a simple mounting platform rather than requiring a complex rigid framework.
Data Source
AI summary
A microprojection array is provided, comprising an approximately planar base and a plurality of microprojections, wherein the array comprises a vaccine and a polymeric material. The array may have multiple layers. The vaccine may be placed in only one layer. In another embodiment of the invention, a method of preventing a disease is provided, comprising insertion into the skin of a patient an array of microprojections comprising a layer which comprises a vaccine for that disease and a polymer.